Sutro Biopharma, Inc. (STRO)
NASDAQ: STRO · Real-Time Price · USD
1.060
+0.040 (3.92%)
At close: Sep 5, 2025, 4:00 PM
1.050
-0.010 (-0.94%)
After-hours: Sep 5, 2025, 7:27 PM EDT

Sutro Biopharma Statistics

Total Valuation

Sutro Biopharma has a market cap or net worth of $89.86 million. The enterprise value is -$95.68 million.

Market Cap89.86M
Enterprise Value -95.68M

Important Dates

The last earnings date was Thursday, August 7, 2025, after market close.

Earnings Date Aug 7, 2025
Ex-Dividend Date n/a

Share Statistics

Sutro Biopharma has 84.77 million shares outstanding. The number of shares has increased by 25.76% in one year.

Current Share Class 84.77M
Shares Outstanding 84.77M
Shares Change (YoY) +25.76%
Shares Change (QoQ) +1.77%
Owned by Insiders (%) 1.59%
Owned by Institutions (%) 46.43%
Float 67.12M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 0.84
Forward PS 2.17
PB Ratio n/a
P/TBV Ratio n/a
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 3.12

Current Ratio 3.12
Quick Ratio 2.87
Debt / Equity n/a
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage -4.70

Financial Efficiency

Return on equity (ROE) is -347.64% and return on invested capital (ROIC) is -124.54%.

Return on Equity (ROE) -347.64%
Return on Assets (ROA) -27.54%
Return on Invested Capital (ROIC) -124.54%
Return on Capital Employed (ROCE) -88.02%
Revenue Per Employee $337,010
Profits Per Employee -$673,216
Employee Count310
Asset Turnover 0.28
Inventory Turnover n/a

Taxes

In the past 12 months, Sutro Biopharma has paid $2.34 million in taxes.

Income Tax 2.34M
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -75.23% in the last 52 weeks. The beta is 1.58, so Sutro Biopharma's price volatility has been higher than the market average.

Beta (5Y) 1.58
52-Week Price Change -75.23%
50-Day Moving Average 0.83
200-Day Moving Average 1.29
Relative Strength Index (RSI) 70.79
Average Volume (20 Days) 519,889

Short Selling Information

The latest short interest is 3.53 million, so 4.16% of the outstanding shares have been sold short.

Short Interest 3.53M
Short Previous Month 3.38M
Short % of Shares Out 4.16%
Short % of Float 5.26%
Short Ratio (days to cover) 7.36

Income Statement

In the last 12 months, Sutro Biopharma had revenue of $104.47 million and -$208.70 million in losses. Loss per share was -$2.51.

Revenue104.47M
Gross Profit 120.95M
Operating Income -165.57M
Pretax Income -97.16M
Net Income -208.70M
EBITDA -158.10M
EBIT -165.57M
Loss Per Share -$2.51
Full Income Statement

Balance Sheet

The company has $205.13 million in cash and $19.59 million in debt, giving a net cash position of $185.54 million or $2.19 per share.

Cash & Cash Equivalents 205.13M
Total Debt 19.59M
Net Cash 185.54M
Net Cash Per Share $2.19
Equity (Book Value) -32.11M
Book Value Per Share -0.38
Working Capital 157.38M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$248.86 million and capital expenditures -$3.16 million, giving a free cash flow of -$252.02 million.

Operating Cash Flow -248.86M
Capital Expenditures -3.16M
Free Cash Flow -252.02M
FCF Per Share -$2.97
Full Cash Flow Statement

Margins

Gross margin is 115.77%, with operating and profit margins of -158.48% and -199.76%.

Gross Margin 115.77%
Operating Margin -158.48%
Pretax Margin -197.52%
Profit Margin -199.76%
EBITDA Margin -151.33%
EBIT Margin -158.48%
FCF Margin n/a

Dividends & Yields

Sutro Biopharma does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -25.76%
Shareholder Yield -25.76%
Earnings Yield -232.25%
FCF Yield -280.45%

Analyst Forecast

The average price target for Sutro Biopharma is $1.97, which is 85.85% higher than the current price. The consensus rating is "Hold".

Price Target $1.97
Price Target Difference 85.85%
Analyst Consensus Hold
Analyst Count 7
Revenue Growth Forecast (5Y) 1.52%
EPS Growth Forecast (5Y) n/a
Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number n/a
Graham Upside n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

Sutro Biopharma has an Altman Z-Score of -5.23 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score -5.23
Piotroski F-Score 1